SCHEMBL10255255

SCHEMBL10255255

CC(C)C(=O)N1CCN(c2cncc(-c3nnc(-c4ccccc4)o3)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 6/20 0.44
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HIF1A Q16665 1/20 0.43
RCE1 Q9Y256 1/20 0.43
ATR Q13535 1/20 0.42
CKS1B P61024 3/20 0.42
SKP1 P63208 3/20 0.42
SKP2 Q13309 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PIM1 P11309 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2A1 P68400 1/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10255318 0.88 PIM2 (0.56) PIM2ALDH1A1HPGDATRCKS1B
SCHEMBL10255788 0.88 NPC1 (0.52) PIM2KDM4EATRCKS1BSKP1
SCHEMBL10255249 0.85 CKS1B (0.57) PIM2KDM4EHPGDATRCKS1B
SCHEMBL10255307 0.85 DGAT1 (0.49) PIM2ATRCKS1BSKP1SKP2
SCHEMBL14822722 0.85 NPC1 (0.56) PIM2KDM4EALDH1A1HPGDATR
SCHEMBL10256348 0.85 RAB9A (0.50) PIM2KDM4EALDH1A1HPGDATR
SCHEMBL10255806 0.84 ATR (0.55) MAPTKDM4EALDH1A1HPGDATR
SCHEMBL10255805 0.84 RAB9A (0.52) PIM2KDM4EALDH1A1HPGDATR
SCHEMBL10255301 0.83 ALDH1A1 (0.53) PIM2KDM4EALDH1A1HPGDATR
SCHEMBL10255214 0.83 GAA (0.48) PIM2MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 PIM2 682/4885MAPT 3458/4885KDM4E 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.